Search Results 1131-1140 of 18037 for monoclonal antibody

1. Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) - Mayo Clinic

   Has had prior anti-cancer monoclonal antibody within 4 weeks of Study Day 1 or who has not recovered from adverse events due to agents administered >4 weeks ...

2. A Study To Evaluate The Effect Of Canakinumab Or Pembrolizumab Given As Monotherapy Or In Combination As Neo-adjuvant Treatment For Subjects With Early Stages NSCLC - Mayo Clinic

   -History of severe hypersensitivity reactions to monoclonal antibodies ... antibody or drug specifically targeting T-cell co-stimulation or immune ...

3. Evaluate Risk/Benefit Of Nab Paclitaxel In Combination With Gemcitabine And Carboplatin Compared To Gemcitabine And Carboplatin In Triple Negative Metastatic Breast Cancer (Or Metastatic Triple Negative Breast Cancer) - Mayo Clinic

   Prior immunotherapy & monoclonal antibody therapy are acceptable. Subjects who received prior cytotoxic chemotherapy after incomplete resection of ...

4. Multinational Clinical Study Comparing Isatuximab, Pomalidomide, And Dexamethasone To Pomalidomide And Dexamethasone In Refractory Or Relapsed And Refractory Multiple Myeloma Patients - Mayo Clinic

   Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action.

5. A Phase 1/​2 Study Of STP938 For Adult Subjects With Relapsed/​Refractory B-Cell And T-Cell Lymphomas - Mayo Clinic

   study drug. - Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or <5 half ...

6. A Study Assessing HMB-002 In Participants With Von Willebrand Disease - Mayo Clinic

   History of clinically significant hypersensitivity associated with monoclonal antibody therapies. Personal history of venous or arterial thrombosis or ...

7. A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis - Mayo Clinic

   A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to ...

8. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer - Mayo Clinic

   ... antibody Patients in Expansion Phase, Cohorts 2 and 3; Previously ... Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to baseline ...

9. Development Of Potential COVID-19 Vaccine And Serological Assay - Mayo Clinic

   Our group has explored the use of genomic RNA/phage display libraries derived from primary human malignant melanoma cells as a means of identifying antibody ...

10. A Study Of LY2951742 In Participants With Chronic Cluster Headache - Mayo Clinic

    Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins. A history or presence of other medical illness that indicates ...